CHPA Plans Pharmacokinetic Trials On Pediatric OTC Cough/Cold Drugs
This article was originally published in The Tan Sheet
Executive Summary
Companies are in discussions with FDA about conducting pharmacokinetic studies to confirm or refine pediatric cough/cold ingredient dosing in children age 2 to 12, according to the Consumer Healthcare Products Association